The bone marrow, a vital organ for blood and immune cell production, is under threat from an unexpected source. Every second, millions of new cells are born, relying on a delicate dance between stem cells, supportive cells, and immune regulators. But as we age, this harmony can turn into a chaotic waltz.
Ageing, inflammation, and genetic mutations can disrupt the communication between these cellular partners, leading to a silent yet dangerous expansion of mutated stem cells. This process, known as clonal hematopoiesis of indeterminate potential (CHIP), affects a significant portion of the elderly population, increasing their risk of blood cancers and cardiovascular diseases.
Myelodysplastic syndrome (MDS), a related disorder, is a silent killer, affecting blood cell production and leading to marrow failure. It progresses to acute myeloid leukemia (AML) in a significant number of cases, making it a critical area of study.
Despite its clinical importance, the bone marrow microenvironment's role in these disorders has been shrouded in mystery. But an international team, led by researchers from EMBL and the University of Basel, has shed light on this complex issue.
Using advanced molecular and spatial analysis techniques, the team uncovered a striking transformation in the bone marrow microenvironment. They identified a population of inflammatory stromal cells, replacing the normal, supportive mesenchymal stromal cells (MSC). These inflammatory MSCs, or iMSCs, release a cocktail of inflammatory signals, attracting and activating T cells, which further amplify the inflammation.
"I was surprised to see such a pronounced change in the bone marrow microenvironment in individuals with CHIP," said Judith Zaugg, co-senior author and EMBL Group Leader.
The researchers also discovered that the mutated hematopoietic cells in MDS do not directly drive this inflammation. Instead, it is the T cells and iMSCs that create a chronic inflammatory environment, suppressing healthy blood formation and promoting vascular remodeling.
"It's intriguing that the mutant cells themselves don't seem to be the primary drivers of inflammation," said Maksim Kholmatov, co-lead author and EMBL alumnus. "It highlights the importance of the bone marrow microenvironment in disease progression."
This discovery positions inflammation as a key player in the early stages of blood disorders. By targeting the bone marrow microenvironment, researchers open up new avenues for preventive and therapeutic strategies. Anti-inflammatory agents and interferon-modulating drugs could potentially preserve bone marrow function in older adults with CHIP, while targeted drug combinations could halt the progression to MDS or AML.
"Our findings provide a foundation for developing preventive therapies that intercept disease progression before leukemia develops," said Borhane Guezguez, co-senior author and Principal Investigator at UMC Mainz.
This work not only advances our understanding of blood disorders but also broadens our knowledge of 'inflammaging,' the chronic inflammation associated with ageing. The bone marrow, once seen as a simple blood production site, is now recognized as a key player in systemic inflammatory ageing.
"Understanding the immune-stromal interactions in the bone marrow provides a new framework for investigating inflammatory remodeling in other myeloid malignancies and advanced leukemia," Zaugg added.
As we continue to unravel the mysteries of the bone marrow microenvironment, we move closer to developing effective strategies to combat blood cancers and other age-related disorders.
